新出现市场报道时间 2026-10-08 20:00

Grant & Eisenhofer 被任命为 Quantum BioPharma 对 CIBC 和 RBC 的集体诉讼中的首席律师

Grant & Eisenhofer 已被任命为对 CIBC 和 RBC 的合并集体诉讼案的首席律师，该诉讼案指控 Quantum BioPharma 股票非法操纵市场。该诉讼涉及 2020 年至 2024 年期间的市场操纵指控。

为什么重要. Quantum BioPharma及其股东可能会寻求重大赔偿，影响涉及的银行的财务状况。

证据

GGlobeNewswire public company news公司披露2026-10-08 20:00
According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date
查看来源
GGlobeNewswire public company news公司披露2026-10-08 20:00
Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd.
查看来源
GGlobeNewswire public company news公司披露2026-10-08 20:00
Once $250 million is reached, the royalty drops to 3% in perpetuity.
查看来源
GGlobeNewswire public company news公司披露2026-10-08 20:00
The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million.
查看来源
GGlobeNewswire public company news公司披露2026-10-08 20:00
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS.
查看来源
GGlobeNewswire public company news公司披露2026-10-08 20:00
08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court…
查看来源
GGlobeNewswire public company news公司披露2026-10-08 20:00
The Quantum Biopharma lawsuit alleged that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. The class action lawsuit filed December 11, 2025, alleges that bet…
查看来源